Exhibit 10.29


 


Certain personally identifiable information contained
in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K.


 


Amendment
to the Loan Agreement dated as of October 15, 2021


 


of January 18, 2022


 


between


 


		1.	Biotechnology Value Fund, L.P.



44 Montgomery Street, 40th
Floor


San Francisco, CA 94104, USA


[***]


(hereinafter
“Lender 1”)


 


		2.	Biotechnology Value Fund II, L.P.



44 Montgomery
Street, 40th Floor


San Francisco,
CA 94104, USA


[***]


(hereinafter “Lender
2”)


 


		3.	Biotechnology Value Trading Fund OS, L.P.



PO Box 309 Ugland House,
Grand Cayman


KY1-1104, Cayman
Islands


[***]


(hereinafter “Lender
3”)


 


(each a “Lender”
and collectively the “Lenders”)


 


and


 


		4.	MoonLake Immunotherapeutics AG



Dorfstrasse 29


6300 Zug, Switzerland


		[***]	



(hereinafter
the “Borrower”)


 


(the Lenders, the Borrower each a
“Party” and collectively the “Parties”)


 




     


     


    

 


Amendment to the
Loan Agreement dated as of October 15, 2021


 


TAble of contents


 


	Preamble	3
	 	 
	1.	Definitions	3
	 	 	 
	2.	Amendment Section 6 (Term and Repayment) of the Loan Agreement	3
	 	 	 
	3.	Continuity	4
	 	 	 
	4.	Term of this Amendment Agreement	4
	 	 	 
	5.	Miscellaneous	4
	 	 	 
	6.	Applicable law and jurisdiction	4



 




    2


     


    

 


Amendment to the
Loan Agreement dated as of October 15, 2021


 


		Preamble	



 


		A.	On October 15, 2021, the Parties entered into a Loan Agreement regarding certain loans in the total amount
of USD 15,000,000 (the “Loan Agreement”).



 


		B.	The Loans (as defined in the Loan Agreement) granted under the Loan Agreement were granted for a fixed
period of time until the Maturity Date (as defined in the Loan Agreement).



 


		C.	The Parties intend to amend the Maturity Date to the earlier of (i) the Transaction Closing (as defined
in the Loan Agreement) and (ii) March 31, 2022, under the terms and conditions set out in this agreement (the “Amendment Agreement”).



 


			Now, therefore, the Parties agree as follows:



 


		1.	Definitions



 


			Capitalized terms used in this Amendment Agreement shall have the respective meanings as set forth
                                                                               in the Loan Agreement.



 


		2.	Amendment Section 6 (Term and Repayment) of the Loan Agreement



 


			The Parties agree to replace Section 6 of the Loan Agreement in its entirety with the following
                                                                               section:



 


			6. 	TERM AND REPAYMENT



 


			The Loans granted hereunder are granted for a fixed period of time until the earlier of (i) as
                                                                               soon as practicable after the Transaction Closing, but no later than two (2) business days, and (ii) March 31, 2022 (the
                                                                               “Maturity Date”).



 


			 The Loans may be repaid in whole or in part by the Borrower at any time on or prior to
                                                                               the Maturity Date.



 






    3


     


    

 


Amendment to the
Loan Agreement dated as of October 15, 2021


 


		3.	Continuity



 


			The existing provisions of the Loan Agreement shall, except
as amended in this Amendment Agreement, continue in full force and effect, and shall be read and construed as one document together with
this Amendment Agreement.



 


		4.	Term of this Amendment Agreement



 


			This Amendment Agreement shall enter into force upon signature by all Parties and shall
                                                                               automatically end upon termination of the Loan Agreement.



 


		5.	Miscellaneous



 


			Section 12 of the Loan Agreement shall apply to this Amendment Agreement.



 


		6.	Applicable law and jurisdiction



 


			This Amendment Agreement shall in all respects be governed by and construed in accordance with Swiss
                                                                               law under the exclusion of its private international law provisions and international treaties.



 


			Any dispute, controversy or claim arising out of, or in relation to, this con-tract, including the
                                                                               validity, invalidity, breach, or termination thereof, shall be subject to the exclusive jurisdiction of the courts of Zug, Canton of
                                                                               Zug, Switzerland.



 


[signature page to follow]


 




    4


     


    

 





Amendment to the
Loan Agreement dated as of October 15, 2021

 








	Lender 1	 
	 	 
	Signature: 	/s/ Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P.	 


 





	Lender 2	 	 
	 	 	 
	Signature: 	/s/ Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P.	 


 


	Lender 3	 	 
	 	 	 
	Signature: 	/s/ Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.	 


 





	Borrower	 
	 	 
	MoonLake Immunotherapeutics AG	 
	 	 
	Signature: 	/s/ Jorge Santos da Silva	 
	Name:	Jorge Santos da Silva	 
	Title:	CEO	 
	 	 	 
	Signature:	/s/ Matthias Bodenstedt	 
	Name:	Matthias Bodenstedt	 
	Title:	CFO	 


 


 


5